Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated.

Slides:

Advertisements

Similar presentations

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Advertisements

Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.

COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results.

A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy

Bo Karlsson, Gunilla Burell, Ulla-Maria Anderberg, Kurt Svärdsudd

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: Results of the phase.

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Psychoeducational groups for adults with ADHD and their significant others (PEGASUS): A pragmatic multicenter and randomized controlled trial T. Hirvikoski,

Psychoeducational groups for adults with ADHD and their significant others (PEGASUS): A pragmatic multicenter and randomized controlled trial T. Hirvikoski,

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Susanne M.

Volume 64, Pages e1-e3 (January 2017)

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Correlation between urinary dose and delayed radiation cystitis after 78Gy intensity- modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up.

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology? Laila König, Henrik.

Clinical Trial Results with OROS® Hydromorphone

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

Alzheimer's disease drug development pipeline: 2018

SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma M. Ashton, N. O'Rourke, N.

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer Delmy Oliva, Mats Nilsson, Bengt-Åke Andersson,

Evolution of Cancer-Related Symptoms Over an 18-Month Period

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Efficacy of Dexmethylphenidate for the Treatment of Fatigue After Cancer Chemotherapy: A Randomized Clinical Trial Elyse E. Lower, MD, Stewart Fleishman,

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Clinical and Translational Radiation Oncology

Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality.

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology? Laila König, Henrik.

Carola Hartel, Elena Nasonova, Martina C. Fuss, Anna V

Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer Hiram A. Gay, Jung Hun Oh, Aditya P.

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced.

Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Jojanneke M. Seinen, Maarten G

Clinical and Translational Radiation Oncology

Treatment with 4Jointz reduces knee pain over 12 weeks of treatment in patients with clinical knee osteoarthritis: a randomised controlled trial L.L.

A neuropathic pain component as a predictor of improvement in pain interference after radiotherapy for painful tumors: A secondary analysis of a prospective.

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.

Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung.

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy Cédric Chevalier,

Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx:

Jean-Emmanuel Bibault, Ingeborg Tinhofer

What is the impact of diabetes mellitus on radiation induced acute proctitis after radical radiotherapy for adenocarcinoma prostate? A prospective longitudinal.

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

Volume 17, Issue 8, Pages (August 2016)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor.

Combined spinal and epidural anaesthesia and maternal intrapartum temperature during vaginal delivery: a randomized clinical trial F.A. de Orange, Passini.

Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer Garrett L. Jensen, Pierre Blanchard, G. Brandon Gunn, Adam.

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Gender differences in irritable bowel syndrome

Pain Response Rates After Conventional Radiation Therapy for Bone Metastases in Prospective Nonrandomized Studies: A Systematic Review Tetsuo Saito,

Aisling Krishnan, Yat Man Tsang, Adéle Stewart-Lord

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed.

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Manual therapy, exercise therapy, or both, in addition to usual care, for osteoarthritis of the hip or knee: a randomized controlled trial. 1: clinical.

Volume 124, Issue 1, Pages (January 2012)

Induction Therapy For Locally Advanced Thymoma

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

R. Parke, S. McGuinness, R. Dixon, A. Jull

Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy Mercy Ofuya, Lucy McParland, Louise Murray,

Presentation transcript:

Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx H. Hauswald, A.D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M.W. Münter, J. Debus Clinical and Translational Radiation Oncology Volume 13, Pages 64-73 (November 2018) DOI: 10.1016/j.ctro.2018.09.005 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Flow-chart of the TPF-C-HIT trial. Clinical and Translational Radiation Oncology 2018 13, 64-73DOI: (10.1016/j.ctro.2018.09.005) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 EORTC-QLQ-C30 Questionnaire functional results (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology 2018 13, 64-73DOI: (10.1016/j.ctro.2018.09.005) Copyright © 2018 The Authors Terms and Conditions

Fig. 3a EORTC-QLQ-C30 Questionnaire gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology 2018 13, 64-73DOI: (10.1016/j.ctro.2018.09.005) Copyright © 2018 The Authors Terms and Conditions

Fig. 3b EORTC-QLQ-C30 Questionnaire non-gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology 2018 13, 64-73DOI: (10.1016/j.ctro.2018.09.005) Copyright © 2018 The Authors Terms and Conditions

Fig. 4a EORTC QLQ H&N 35 single item scale scores (oral part, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology 2018 13, 64-73DOI: (10.1016/j.ctro.2018.09.005) Copyright © 2018 The Authors Terms and Conditions

Fig. 4b EORTC QLQ H&N 35 single item scale scores (gastrointestinal, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology 2018 13, 64-73DOI: (10.1016/j.ctro.2018.09.005) Copyright © 2018 The Authors Terms and Conditions

Fig. 4c EORTC QLQ H&N 35 single item scale scores (other symptoms, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology 2018 13, 64-73DOI: (10.1016/j.ctro.2018.09.005) Copyright © 2018 The Authors Terms and Conditions